Array-based comparative genomic hybridization (aCGH) is a reference high-throughput technology for detecting large pathogenic or polymorphic copy-number variations in the human genome; however, a number of quantitative monogenic mutations, such as smaller heterozygous deletions or duplications, are usually missed in most disease genes when proper multiplex ligation-dependent probe assays are not performed.
Neuromuscular disorders (NMDs) 9 are a highly heterogeneous group of genetically determined diseases encompassing many conditions that, directly or indirectly, impair muscle function by affecting the muscles and/or their nervous control. In the annually published gene table of NMDs (http://www.musclegenetable. org) (1 ) , 495 clinical entries and 272 distinct causative nuclear genes have been annotated to date. Genetic and clinical redundancy reflects the broad phenotypic variability included under the term "neuromuscular disorders," embracing myopathies, cardiomyopathies, and neuromyopathies. In addition, at least 99 mapped NMD loci await identification of the causative gene (1 ) , which will extend the number of genes involved in neuromuscular phenotypes.
NMDs are either genetically heterogeneous, in that the same disease may be caused by mutations in many different genes (2 ), or clinically heterogeneous, when the same gene may be mutated in several different clinical conditions (3 ) . Consequently, molecular diagnosis can be very expensive and time-consuming, requiring a multistep methodological approach and sometimes adding frustration because of the high number of genes that need to be analyzed. Exome sequencing based on next-generation sequencing will be helpful, but even with this powerful technology, copynumber mutations can remain undetected.
A wide range of deleterious mutations have been detected in NMD genes. They include singlenucleotide substitutions that may affect gene expression differently, short insertions or deletions of bases, large deletions or duplications, and other complex chromosomal rearrangements.
When we reviewed the freely available mutation databases (4 ) to determine the impact of different types of mutations in NMD genes, we observed that most of the characterized pathologic alleles correspond to point mutations and that other mutational mechanisms, such as deletions or duplications, are probably underestimated. About 5% to 6% of gene mutations causing inherited disorders are large deletions or duplications (5, 6 ) , although this percentage is dependent on genomic regions and the techniques used.
Array-based comparative genomic hybridization (aCGH) is the most widely used technology for detecting copy-number variations (CNVs) and for their mapping along chromosomes (7 ) , and its use is based on the resolution level of the specific design and the platform used (8 ) .
aCGH has proved an excellent technique for detecting DNA copy-number changes in the human genome (9 ) . It has been used for the analysis of tumor genomes (10 ) and is increasingly used for the genetic testing of individuals with unexplained developmental delay or multiple congenital anomalies (11, 12 ) . In addition, new high-density technologies (13 ) and the possibility of designing customized aCGH focused on specific chromosomal locations for increasing the resolution in a targeted genomic region of interest (14, 15 ) have enhanced the spectrum of moleculardiagnostic applications.
In NMD molecular diagnosis (16 -18 ) , aCGH applications initially focused on Duchenne and Becker muscular dystrophies, which are caused predominantly by DMD 10 (dystrophin) deletions (75%) or duplications (10%) on the X chromosome (19 ) . Other aCGH designs have focused on sarcoglycanopathies (20 ) , collagen VI-related myopathies (21 ) , and amyotrophic lateral sclerosis (22 ) . To date, there are either general or gene-specific aCGH designs, but general arrays have low resolution, whereas gene-specific arrays are useful only when the genetic cause is already suspected. This is not the case for the majority of NMDs characterized by high genetic heterogeneity, for which a comprehensive aCGH design targeting all NMDs could be very useful.
We describe gene selection, the design strategy, and experimental validation of a customized exonspecific oligonucleotide CGH array that we named "Motor Chip" (present release NMDv02.15-Hg18). Motor Chip is capable of testing 425 nuclear genes simultaneously, including 245 disease genes already clearly involved in NMDs and 180 selected genes that are possible candidates in novel neuromuscular phenotypes. Using the Motor Chip to investigate a panel of NMD patients with no previous molecular characterization, we identified the first case of limb girdle muscular dystrophy type 2C (LGMD2C) caused by 2 distinct deletions that inactivate both alleles of the SGCG [sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein)] gene.
Materials and Methods

REFERENCE DNA SAMPLES
Anonymous blood samples were collected into EDTAcontaining Vacutainer tubes (BD) from healthy and unrelated individuals of the same ethnic origin. Genomic DNA was isolated by phenol/chloroform extraction. Written informed consent was obtained from all participants (patients and controls), and the protocol was approved by the Ethics Committee of the Seconda Università degli Studi di Napoli (approval no. 862/2008).
After DNA quantification (see Supplemental Materials and Methods in the Data Supplement that accompanies the online version of this article at http:// www.clinchem.org/content/vol57/issue11), 6 sexmatched DNA samples were pooled and used as male or female reference DNA samples in aCGH experiments.
DOUBLE-BLIND DNA SAMPLES
We used DNA samples from patients with deletions or duplications involving genes included in the Motor Chip design that had previously been detected with alternative diagnostic methods (see Table 1 and Supplemental Materials and Methods in the online Data Supplement). In addition, we used DNA samples from patients with NMDs and an incomplete molecular diagnosis, as well as samples from patients with an NMD clinical diagnosis alone (see Table 1 in the online Data Supplement). Additional DNA samples from healthy individuals were analyzed as negative controls. All DNA samples were blind-tested in aCGH experiments.
GENE SELECTION AND aCGH DESIGN STRATEGY
We selected 245 NMD genes reported in the NMD gene table (1 ) and classified according to 16 different phenotypes (see Table 2 in the online Data Supplement).
Because not all disease genes have been identified, we also included an additional 180 genes (see Table 2 in the online Data Supplement) that we considered putative candidate genes according to criteria indicated in the note to Table 2 in the online Data Supplement. We have included 425 genes in the present release of the Motor Chip. The design was based on 2 principal criteria: the selection of a competitive microarray platform and an affordable cost of the test per sample. We used the Agilent oligonucleotide-based microarray technology (23 ) and the SurePrint G3 8ϫ60K format (59 090 available features), currently the most cost-effective option (see Table 3 in the online Data Supplement).
Probe selection was performed by using the Webbased Agilent eArray database (version 5.0; Agilent Technologies, https://earray.chem.agilent.com/earray/) and choosing from among 24.3 ϫ 10 6 computationally validated oligonucleotide probes (NCBI Build 36.1, Hg18). We selected only a limited number of probes (2132 features, 4.8%) with the eArray Genomic Tiling option to design oligonucleotide probes spanning specific chromosomal regions inadequately represented in the Agilent database. For the Motor Chip, we designed exon-specific oligonucleotide probes to obtain full coverage of the coding sequence of each gene (24, 25 ) .
The selected 425 genes correspond to 40 362 512 bp of genomic sequence and to 3 383 769 bp of coding sequence covered with 44 379 oligonucleotide probes (99.8% coverage). The number of probes for each group, the percentage of custom probes, and the mean number of probes per gene are summarized in Table 1 .
THE DMD GENE
For DMD, in which about 85% of the mutations are deletions or duplications (19 ), we selected partially overlapping probes (15 bp as the maximum-acceptable overlap) covering all of the exons and 200 bp to the 5Ј and 3Ј intronic sides. We also selected intragenic probes spaced 2000 bp apart to cover the entire DMD gene (see Fig. 1A in the online Data Supplement).
OTHER GENES
For all of the other selected genes, we designed partially overlapping probes (15 bp as the maximum-acceptable overlap) that covered only all of the exons and the 5Ј and 3Ј untranslated regions (see Fig. 1B in the online Data Supplement). Alternatively spliced isoforms were also considered. To obtain reliable calls, we selected at least 3 probes per exon (26 ) . We also selected probes spaced 250 bp apart in a 2000-bp genomic region at the 5Ј end of the gene that should include the putative promoter (see Fig. 1C in the online Data Supplement).
To obtain whole-genome coverage, we randomly filled the residual free space on the array (14 711 features, approximately 23.4%) with probes from the commercially available Agilent Human Genome 44K CGH Microarray.
Biological features were randomly distributed on the microarray. The routinely used Human CGH 1K Agilent Normalization Probe Group (1262 features) and the Human CGH 1K Agilent Replicate Probe Group (5000 features) were also included in the design.
Results
VALIDATION STRATEGY
After an overall evaluation of the Motor Chip design (see Supplemental Materials and Methods in the online Data Supplement), we analyzed 56 double-blind DNA samples (see Table 1 in the online Data Supplement). These samples included 26 from patients in whom genomic imbalances involving NMD genes had previously been detected by different methods [PCR, Log-PCR, multiplex ligation-dependent probe amplification (MLPA), quantitative PCR, and aCGH], 7 from patients with NMDs and an incomplete molecular diagnosis (autosomal recessive inheritance and a causative point mutation identified in only 1 allele), and 19 from patients with an NMD clinical diagnosis alone. Three samples from affected individuals with deleterious mutations undetectable with the Motor Chip, 1 sample from a healthy carrier individual, and 8 anonymous samples from healthy individuals were also included as negative controls.
The Motor Chip detected no clinically relevant genomic imbalances in any of the 12 negative controls, with the exception of a previously undetected aneuploid karyotype (47,XYY) in sample no. 40, from a dystrophic patient with a DMD nonsense mutation (see Fig. 2 in the online Data Supplement). This result was validated by MLPA, confirming that the genomic backbone of the Motor Chip was also able to detect more complex and unexpected chromosomal imbalances. Annotated CNVs were detected in negative controls and were also present in some patients (see Table 4 in the online Data Supplement).
DOUBLE-BLIND DIAGNOSIS OF KNOWN MUTATIONS
For samples from patients with deleterious genomic imbalances, the results obtained with the Motor Chip were consistent with those obtained by different methods (Table 2 ; see Table 1 in the online Data Supplement).
Nine samples (nos. 1-3, 5, 7-9, 11, and 12) presented hemizygous or heterozygous copy-number imbalances involving 1, 2, or more DMD exons (see Fig. 3 in the online Data Supplement). In these cases, the Motor Chip was able to define breakpoint boundaries more precisely than previously used methods because of more accurate coverage of DMD intragenic regions (Table 2) . Two unrelated samples (nos. 4 and 10) presented an isolated homozygous deletion of exon 7 in SGCG (see 11 ; SPATA13 (spermatogenesis associated 13), and C1QTNF9 (C1q and tumor necrosis factor related protein 9). Two of these genes, SGCG and SACS, are NMD genes (see Fig. 7 in the online Data Supplement). CNVs covering this region have previously been reported (27, 28 ) . Two of these patients (nos. 29 and 32) also presented a SACS point mutation on the second allele that produced the observed recessive neuromuscular phenotype (29, 30 ) . Finally, 2 samples (nos. 38 and 39) presented a wide heterozygous deletion and a duplication, respectively, both of which involved the PMP22 (peripheral myelin protein 22) and other flanking genes (see Fig. 8 in the online Data Supplement).
NOVEL FINDINGS IN PATIENTS WITH A KNOWN MUTATION IN A SINGLE ALLELE
For samples from patients with an incomplete molecular diagnosis, 4 patients (nos. 24, 25, 26, and 33) presented point mutations in SPG11, and 3 patients (nos. 21, 35, and 36) presented mutations in SETX (senataxin), ZFYVE26 (zinc finger, FYVE domain containing 26), and SACS, respectively. When analyzed on the Motor Chip, only sample no. 21 showed a heterozygous deletion of exons 16 -24 in SETX, confirming the diagnosis of autosomal recessive ataxia with oculomotor apraxia type 2 (AOA2). This result was confirmed by long-range PCR and direct sequencing of the breakpoint ( Fig. 1 ; see Supplemental Materials and Methods in the online Data Supplement). The deletion (NG_007946.1:g.62507_83156delins25) was perfectly coincident with that previously described in an unrelated AOA2 patient (31 ) , confirming that deleterious copy-number changes are not infrequent occurrences in SETX (32 ) . No clinically relevant deleterious genomic imbalances were detected in the other samples.
NOVEL FINDINGS IN PATIENTS WITHOUT MUTATIONS
Finally, we analyzed 19 samples with an NMD clinical diagnosis alone, 3 of which were from patients with familial spastic paraparesis or ataxia with an autosomal dominant inheritance (sample nos. 16, 34, and 37), whereas the others (sample nos. 41-56) were mainly from patients with a generic diagnosis of LGMD. In 4 of these samples (nos. 42, 45, 55, and 56), the Motor Chip detected copy-number changes in 3 different NMD genes.
Sample no. 42 corresponded to a familial case with a severe LGMD phenotype. We detected a wide 1 (2) 4 (7) 7 (12) 10 ( 3 (4) 10 (13) 18 (23) 28 ( 3 (7) 10 (17) 13 (23) 23 (44) a Chr, chromosome; Min (Max), minimum (maximum); DEL, deletion; Het, heterozygote; DUP, duplication; Hom, homozygote; Hem, hemizygote, UTR, untranslated region. (33 ) . We used real-time PCR to confirm and better define the extension of this duplication (Fig. 2) . Sample no. 45 corresponded to a familial case with an LGMD/Becker muscular dystrophy-like phenotype. We detected an intragenic heterozygous duplication in LAMA2 (laminin, alpha 2) spanning about 48.8 kb and involving exons 5-12. The copy-number change was confirmed by real-time PCR, which also better positioned the 5Ј and 3Ј breakpoints to the 129503539 -129507201 and 129573766 -129593644 intervals, respectively (Fig. 3A) . These results were perfectly coincident in 2 affected sisters of the proband, but after direct sequencing of all coding exons, we were unable to identify any causative mutation on the second allele. 
Motor Chip: A CGH Microarray for Neuromuscular Disorders
We identified another copy-number change in LAMA2 in sample no. 55, a sporadic case of generic myopathy with sarcotubular proliferation. We detected a heterozygous deletion of about 164.4 kb that removed exons 13-37. The breakpoint was precisely mapped by long-range PCR and direct sequencing (NG_008678.1:g.347377_511797del) (Fig. 3B) . This rearrangement was maternally inherited, and all attempts to identify the causative mutation on the second allele proved ineffective. Direct sequencing of all coding exons highlighted only 3 single-nucleotide polymorphisms (rs17057184, NM_000426.3:c.6279C/T (p.A2093A), and rs6569606). One (NM_000426.3: c.6279C/T) was located in exon 45, which was not involved in a copy-number change, and was shown to be heterozygous by genomic DNA analysis. An mRNA analysis of the patient's lymphocytes revealed that this single-nucleotide polymorphism was no longer heterozygous, indicating that the other allele was not expressed.
Sample no. 56 corresponded to a familial case with a severe LGMD phenotype. Analysis with the Motor Chip revealed this individual to be compound heterozygous for 2 different wide deletions involving SGCG, which caused LGMD2C (34 ) . One allele presented the same deletion of about 1.5 Mb involving 7 genes (including SGCG and SACS) described above for sample nos. 27, 28, 29, 30, and 32 (Fig. 4A) . On the other allele, we detected a shorter deletion of about 114.5 kb that removed the first 6 exons of SGCG (Fig. 4A) .
By real-time PCR and long-range PCR we confirmed both copy-number changes and further refined the breakpoints. The 1.5-Mb microdeletion was coincident with that previously reported by Breckpot et al. (35 ) caused by nonallelic homologous recombination involving highly homologous segmental duplications in the 5Ј and 3Ј breakpoint-containing regions, which we narrowed down to the 22402586 -22407180 and 23830032-23832533 intervals, respectively (Fig.  4A) . Conversely, the breakpoint of the shorter microdeletion was precisely mapped [chr13: g.22620716_22789085del (NCBI build 36.1)] (Fig. 4B) . It is most likely due to homologous recombination me- Sample no. 42 showed a wide heterozygous duplication of about 735 kb, which was detected with 73 probes. The duplication involved 10 genes at 2p13.3, as well as the first 20 exons of DYSF. In the UCSC graphic view, the blue bar corresponds to the minimal aberration length, and the flanking red bars indicate the 5Ј and 3Ј breakpoint boundaries as determined with the Motor Chip. The results of genomic quantification by real-time PCR are schematically represented (bottom). The middle base-pair position of each amplicon along the chromosome (chr) is indicated by a square or a circle (normal or duplicated status, respectively, compared with controls). Consequently, the 5Ј and 3Ј breakpoints were restricted to the 70864793-70898437 and 71634262-71635232 intervals, respectively. (A), Sample no. 45 showed an intragenic heterozygous duplication of about 48.8 kb, which was detected with 23 probes. The duplication involved LAMA2 exons 5-10. In the UCSC graphic view, the blue bar corresponds to the minimal aberration length, and the flanking red bars indicate the 5Ј and 3Ј breakpoint boundaries as determined with the Motor Chip. The results of genomic quantification by real-time PCR are represented schematically (bottom). The middle base-pair position of each amplicon along the chromosome (chr) is indicated by a square or a circle (normal or duplicated status, respectively, compared with controls). The 5Ј and 3Ј breakpoints were restricted to the 129503539 -129507201 and 129573766 -129593644 intervals, respectively. This copy-number change was also present in 2 affected sisters (ID nos. 3158 and 3162) of the proband. (B), Sample no. 55 showed an intragenic heterozygous deletion of about 164.4 kb, which was detected with 94 probes. This deletion involved LAMA2 exons 13-37. In the UCSC graphic view, the blue bar corresponds to the minimal aberration length, and the flanking red bars indicate the 5Ј and 3Ј breakpoint boundaries as determined with the Motor Chip. The extension of the deletion and the breakpoint position were precisely mapped by long-range PCR and direct sequencing (bottom).
Motor Chip: A CGH Microarray for Neuromuscular Disorders diated by 2 Alu elements with a high sequence similarity (AluSp at the 5Ј end and AluY at the 3Ј end).
Discussion
The Motor Chip is an NMD-focused oligonucleotidebased CGH array and represents the first comprehensive approach to analyzing deleterious copy-number changes in a wide set of NMD genes. The release presented here (NMDv02.15-Hg18) includes 425 nuclear genes, 245 of which are already implicated in neuromuscular phenotypes. The exon-specific probe selection strategy used in the Motor Chip design permitted not only full coverage of the coding sequence for all of the selected genes by using only 44 379 features but also a reduction in the costs per test (see Table 3 in the online Data Supplement), an added value for laboratory use. The technical protocol can be carried out in 6 person-hours (see Table 3 in the online Data Supplement), and it is suitable for use in automated liquidhandling systems.
There is a commercially available MLPA assay (MRC-Holland), which is frequently used as an alternative method for detecting copy-number changes, for (A), Sample no. 56 was shown to be compound heterozygous for 2 distinct deletions involving SGCG. One allele presented a wide deletion of about 1.5 Mb, which was detected with 308 probes. This deletion included genes SGCG, SACS, TNFRSF19, MIPEP, PCOTH, SPATA13, and C1QTNF9. On the other allele, 13 probes detected a shorter deletion of about 114.5 kb that removed the first 6 exons of SGCG. In the UCSC graphic view, the blue bar corresponds to the minimal aberration length, and the flanking red bars indicate the 5Ј and 3Ј breakpoint boundaries as determined with the Motor Chip. The results of genomic quantification by real-time PCR are represented schematically (bottom). The middle base-pair position of each amplicon along the chromosome is indicated by a square or a triangle (normal or deleted status, respectively, compared with controls). Green bars highlight homologous segment-duplicated regions in which recombination occurs. (B), By long-range PCR and direct sequencing, the extension of the shorter deletion and breakpoint position were precisely mapped. The deletion is 168 369 bp and is caused by an Alu element-mediated homologous recombination.
only 44 of the 245 NMD genes included in the Motor Chip. The Motor Chip is cheaper and less timeconsuming than MLPA analysis, especially when a panel of candidate genes needs to be investigated.
Validation experiments demonstrated the diagnostic sensitivity and specificity of the Motor Chip design, with 100% concordance between Motor Chip results and those generated by other methods. Of all of the double-blinded DNA samples analyzed, 26 with previously detected pathologic chromosomal imbalances were correctly addressed with the Motor Chip. For the other 27 samples with an incomplete or undetermined molecular diagnosis, only 5 showed previously undetected copy-number changes in NMD genes.
By detecting a wide heterozygous intragenic deletion in SETX, we confirmed the clinical diagnosis of AOA2 for patient no. 21. We also provided the molecular diagnosis of LGMD2C for patient no. 56, who was shown to be a compound heterozygote for 2 distinct wide microdeletions involving SGCG. Interestingly, 1 of these alleles corresponded to a previously reported CNV (27, 28 ) , which was also detected in other samples analyzed in this study together with SACS point mutations, producing autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) (29, 30, 35 ) . Recently, a combined LGMD2C/ARSACS phenotype in a 10-year-old girl was also reported as being due to a similar homozygous microdeletion (36 ) . The individual we have described is the first LGMD2C case with distinct microdeletions involving both SGCG copies. Exonic deletions are rare events in sarcoglycanopathies; however, our results suggest that screening for exonic deletions/duplications or more-complex copynumber changes should be carried out for patients in whom a mutation has not been identified in both alleles, as well as in apparently homozygous cases in which segregation of the mutations cannot be confirmed in the parents.
Copy-number imbalances involving DYSF or LAMA2 were also detected in another 3 patients (nos. 42, 45, and 55). Their pathogenic significance was unclear, however. In particular, the observed LAMA2 intragenic duplication and deletion were in frame and apparently without causative mutations on the second allele. CNVs resembling these rearrangements have not been annotated in the Database of Genomic Variants (http://projects.tcag.ca/variation/); however, intragenic copy-number changes for LAMA2 have been reported very recently (37 ) .
The Motor Chip was therefore able to provide a molecular diagnosis in 2 of 27 of these cases, a result consistent with the possible role of deleterious copynumber imbalances in NMDs, which have been estimated at 5%-10%.
Compared with the commercially available Agilent Human Genome CGH Microarrays, the Motor Chip design presents further advantages. They include greater efficiency in detecting intragenic deleterious copy-number changes and a reduction in CNV calls of uncertain pathogenic significance. As highlighted in Table 2 , the Motor Chip contains more probes than standard Agilent aCGH designs for most of the pathogenic rearrangements that have been identified. Eight intragenic copy-number changes were undetectable with any of the Agilent aCGH designs considered. Compared with the Motor Chip, these copy-number changes showed a detection rate of about 41.9%, 54.8%, 67.7%, and 77.4% for the 60K, 180K, 244K, and 400K designs, respectively. Therefore, for most NMD monogenic disorders, full exon-specific coverage is necessary to detect causative mutations. As very recently proposed (25 ) , this approach may be applied to a wide range of different clinical conditions.
The Motor Chip also included 180 putative NMD genes, which were selected on the basis of their role in neuromuscular functions. It was designed to be a tool for both enhancing molecular diagnosis and discovering novel disease genes. The oligonucleotide probes selected for full exonic coverage of these genes provided satisfactory signal quality for both channels in the validation experiments performed to date. Only by using the Motor Chip in routine laboratory analyses will it be possible to verify the potential involvement of these genes in neuromuscular diseases.
Oligonucleotide-based microarrays can be updated quickly and easily. For the Motor Chip, selected probes were grouped according to the phenotypic classification of genes described in Table 1 . Consequently, features covering a specific gene can be easily added or removed to rapidly enhance array design. Importantly, subsets of these experimentally validated probes could be used in a dedicated microarray design for investigating specific NMD genes, which would further reduce the costs per test.
Unlike commonly used microarray design strategies (in which probes are spaced specifically at high density along the chromosomal regions of interest), all of the genes included in the Motor Chip, with the exception of DMD, were covered with exon-specific oligonucleotide probes alone. Although this approach reduces the number of probes required, contains costs, and increases the detection rate, it might make breakpoint boundary characterization more difficult. This feature can be considered a minor criticism. In many cases, breakpoint boundaries can be mapped precisely by long-range PCR with appropriately designed primer pairs. For genes characterized by wide introns, we intend to add other suitably spaced intragenic probes to the next release of the Motor Chip. Very recently, gen-eral recommendations for performing aCGH-based diagnostic tests have advised using a uniform genome coverage with a resolution of 5 Mb to 400 kb throughout the genome (12 ) . The backbone of the next version of the Motor Chip will therefore be redesigned with probes spaced approximately 300 kb apart throughout the genome, for an estimated resolution of about 1 Mb. The current release, in which the entire genome is covered by randomly selected probes, is nevertheless able to identify unexpected genomic imbalances, as confirmed by the detection of both annotated CNVs and the aneuploid (47,XYY) karyotype in sample no. 40.
The molecular diagnosis of CNVs in NMDs will be facilitated by use of the Motor Chip. Present and future releases of the Motor Chip are freely accessible to other laboratories on request via the Web-based eArray interface.
